Concomitant alcohol and sedative-hypnotic drug use among the elderly in Norway
Concomitant alcohol and sedative-hypnotic drug use among the elderly in Norway
复制标题
DOI：
10.1177/1455072516683896
复制
发表时间：
2017-02-01
影响因子：
1.7
通讯作者：
Rossow, Ingeborg
中科院分区：
文献类型：
--
作者：
Bye, Elin Kristin;Rossow, Ingeborg
背景：与其他年龄段相比，老年人使用镇静催眠药物(即镇静剂和安眠药)的频率更高。同时使用酒精和镇静催眠药是老年人意外伤害的一个特别高的风险因素。然而，很少有研究涉及伴随酒精和镇静催眠药物使用的流行率，而且对这种使用的特点的了解也很少。目的：了解老年人同时饮酒和镇静催眠药物使用情况，探讨老年人同时使用酒精和镇静催眠药物的特点。数据和方法：数据来源于挪威2012-2015年期间进行的横断面人口调查(亚样本60-79年：N-1920)。结果：受访者报告了在过去12个月中使用镇静剂(镇静剂)、催眠药(安眠药)和饮酒的频率。25%的人报告使用了催眠药物，19%的人报告在过去一年中同时使用了这种药物和酒精。同时使用酒精和药物的报告增加了6%。结论：女性、危险酒精使用者、非工作受访者以及低收入群体和独居者报告的伴随使用更多。卫生人员需要考虑与同时使用相关的风险，并相应地通知他们的患者。
Background: Sedative-hypnotic drugs (i. e., tranquilizers and sleeping pills) are more often used among the elderly compared to other age groups. Concomitant use of alcohol and sedativehypnotic drugs constitutes a particularly high risk factor for accidental injuries among the elderly. However, few studies have addressed the prevalence of concomitant alcohol and sedativehypnotic drug use and knowledge about the characteristics of such use is meagre. Aim: To assess the prevalence of concomitant alcohol and sedative-hypnotic drug use among elderly people and to explore the characteristics of such concomitant use. Data and method: Data stemmed from cross-sectional population surveys in Norway, conducted in the period 2012-2015 (sub-sample 60-79 years: N - 1920). Results: Respondents reported frequencies of use of sedatives (tranquilizers), hypnotics (sleeping pills) and alcohol consumption in the preceding 12 months. Sedativehypnotic drug use was reported by 25%, and 19% reported both such drug use and alcohol use in the past year. Concomitant use, suggesting simultaneous intake of alcohol and drugs, was reported by 6%. Conclusions: Concomitant use was more often reported by women, hazardous alcohol users, non-working respondents, and by those in the lower income groups and those living alone. Health personnel need to take into consideration the risks associated with concomitant use and to inform their patients accordingly.